Dental anesthesia depends fundamentally on understanding the pharmacological properties distinguishing available local anesthetic agents. Each agent exhibits unique onset times, duration of action, bone penetration characteristics, and toxicity profiles that guide clinical selection. This comprehensive review addresses the chemical classification, pharmacokinetics, and specific clinical applications of agents commonly used in dental practice.
Amide Anesthetics: Lidocaine
Lidocaine remains the reference standard local anesthetic against which other agents are compared. As an amide agent (containing an amide linkage in its chemical structure), lidocaine undergoes hepatic metabolism via microsomal N-dealkylation, making its elimination dependent on liver function. At 1-2% concentration with 1:100,000 epinephrine, lidocaine achieves onset in 3-5 minutes and provides anesthesia for 30-60 minutes depending on concentration and vasoconstrictor presence. Maximum recommended dose is 300 milligrams (approximately 15 cartridges of 2% solution) in a single appointment for healthy adults, or 4.5 milligrams per kilogram body weight for patients with hepatic or renal compromise.
Lidocaine penetrates bone poorly, making pure infiltration anesthesia insufficient for mandibular molars; inferior alveolar nerve blocks remain necessary for adequate mandibular anesthesia. The local pKa of 7.9 results in moderate diffusion across nerve sheaths; onset time of 3-5 minutes is reasonably rapid but not instantaneous. Lidocaine solution without epinephrine demonstrates vasodilatation properties, requiring higher concentrations (3%) for adequate hemostasis. Systemic toxicity from overdose manifests first as perioral paresthesias and tremors, progressing to seizures (at plasma concentrations of 5-10 micrograms per milliliter) and cardiac arrhythmias at higher levels.
Amide Anesthetics: Articaine
Articaine, a newer amide agent, demonstrates superior bone penetration compared to lidocaine due to its thiophene ring structure (rather than benzene), allowing approximately 40% bone penetration versus lidocaine's 5-10%. This property enables 4% articaine infiltration to achieve mandibular anesthesia similar to 2% lidocaine with nerve blocks. At 4% concentration with 1:100,000 epinephrine, articaine achieves onset in 2-3 minutes and provides anesthesia for 45-90 minutes. Maximum recommended dose is 50 milligrams (approximately 6.25 cartridges of 4% solution) per appointment in healthy adults, lower than lidocaine due to higher concentration.
Articaine metabolizes via serum pseudocholinesterase to articainic acid (the primary metabolite) and liver metabolism, making elimination less dependent on hepatic function than lidocaine. This characteristic benefits patients with hepatic insufficiency. Systemic toxicity thresholds are similar to lidocaine, though the higher concentration (4% vs. 2%) means lower cartridge volumes are needed, reducing injection volume and physical discomfort. Clinical studies demonstrate superior pain control for mandibular molars using articaine infiltration (90% successful anesthesia) versus lidocaine infiltration (40-50% success), making it preferred for lower posterior tooth treatment.
Amide Anesthetics: Bupivacaine
Bupivacaine, a long-acting amide (pKa 8.1), achieves slower onset (5-10 minutes) but provides extended anesthesia duration of 4-8 hours, making it optimal for post-operative pain management. At 0.5% concentration with 1:200,000 epinephrine, bupivacaine maximum dose is 90 milligrams (approximately 9 cartridges of 0.5% solution) per appointment. The extended duration reflects superior protein binding (95% vs. 65-80% for lidocaine) and lipophilicity, increasing tissue penetration and nerve fiber binding.
Bupivacaine demonstrates cardiac toxicity at lower doses than lidocaine; plasma concentrations exceeding 3-4 micrograms per milliliter may cause dysrhythmias and cardiac depression, whereas lidocaine requires 5-10 micrograms per milliliter. This narrow safety margin makes strict adherence to maximum recommended doses essential. Bupivacaine is contraindicated in patients with severe bradycardia or atrioventricular conduction abnormalities. Clinical applications in dentistry include oral surgery (providing 4-8 hours post-operative anesthesia), implant placement (reducing post-operative pain medications), and endodontic treatment in patients with anticipated post-operative discomfort.
Amide Anesthetics: Prilocaine
Prilocaine, a proprietary amide with rapid metabolism, achieves onset in 3-5 minutes and duration of 30-45 minutes. At 3-4% concentration with 1:200,000 epinephrine, prilocaine maximum dose is 400 milligrams per appointment (60 milligrams per kilogram body weight). The primary metabolite, o-toluidine, can oxidize hemoglobin to methemoglobin, potentially causing cyanosis and dyspnea. This risk increases significantly when total doses exceed 600 milligrams or in patients with baseline methemoglobinemia, glucose-6-phosphate dehydrogenase deficiency, or anemia.
Prilocaine's rapid hepatic metabolism (via hydrolysis) makes it advantageous in patients with pseudocholinesterase deficiency (who metabolize articaine slowly), though absolute maximum doses still apply. The cyanosis risk, though rare at dental dosages, limits widespread adoption compared to lidocaine and articaine. Prilocaine is best reserved for shorter procedures with limited anesthetic volume requirements, or in specific patient populations where metabolic advantages outweigh toxicity concerns.
Ester Anesthetics and Hypersensitivity
Procaine and tetracaine, ester-class anesthetics, undergo plasma hydrolysis by pseudocholinesterase, producing para-aminobenzoic acid (PABA)—a common allergen. True IgE-mediated allergy to ester anesthetics occurs in 2-4% of allergic patients, whereas amide allergy is exceptionally rare (<1 in 10 million cases). Most "allergic reactions" to dental anesthetics result from vasovagal responses, infection-related toxicity, or methylparaben additives (which are structurally similar to PABA). Ester anesthetics are rarely used in modern dentistry; amides are preferred due to superior efficacy, duration, and lower allergy risk.
Vasoconstrictors: Epinephrine Pharmacology
Epinephrine (adrenaline) at concentrations of 1:100,000 or 1:200,000 reduces blood flow through local vasoconstriction, significantly extending anesthetic duration and improving hemostasis. Epinephrine at 1:100,000 increases lidocaine duration from 30 minutes to 60+ minutes and articaine from 45 minutes to 90+ minutes. Maximum epinephrine dose in healthy adults is 0.2 milligrams per appointment; in patients with cardiac history (myocardial infarction, arrhythmia), maximum is 0.04 milligrams.
Epinephrine activates alpha-2 adrenergic receptors (causing vasoconstriction) and beta-1 receptors (increasing heart rate and contractility). Patients with uncontrolled hypertension, recent myocardial infarction, or severe arrhythmias warrant avoidance of epinephrine or use of 1:200,000 concentrations with minimal volume. Systemic absorption of epinephrine produces tachycardia, tremor, and anxiety; these effects resolve within 5-10 minutes post-injection but require clinical recognition to distinguish from allergic reactions.
Vasoconstrictors: Felypressin and Alternatives
Felypressin (a synthetic vasopressin derivative) provides vasoconstriction through V1 receptor activation without adrenergic effects, making it preferable in cardiac patients. However, felypressin is not available in North American dental anesthetic formulations and is primarily used internationally. Felypressin duration extension is less pronounced than epinephrine; lidocaine with felypressin provides approximately 45-50 minutes anesthesia (versus 60+ minutes with epinephrine). No vasoconstrictor may be used in select patients, though plain solutions (without epinephrine) provide shorter anesthesia duration and poor hemostasis.
Clinical Selection Algorithm
Typical procedure selection: routine restorations, periodontal scaling, simple extractions use 2% lidocaine with 1:100,000 epinephrine. Mandibular molar treatment favors 4% articaine with 1:100,000 epinephrine for superior bone penetration and higher success rates. Oral surgery, implant placement, and anticipated post-operative discomfort warrant bupivacaine (0.5% with 1:200,000 epinephrine) for extended anesthesia. Cardiac compromise necessitates plain solutions or 1:200,000 epinephrine concentrations with minimal volumes. Ester-allergic patients can safely receive any amide anesthetic.
Metabolism and Drug Interactions
Amide anesthetic metabolism depends on hepatic microsomal oxidation and N-dealkylation; patients with severe hepatic disease, advanced cirrhosis, or hepatitis require dose reduction. Renal disease delays elimination of metabolites but less significantly affects parent compounds. Interactions with macrolide antibiotics (which inhibit cytochrome P450), antifungals, or protease inhibitors may increase anesthetic plasma levels; dose adjustment may be warranted. Elderly patients (>65 years) typically metabolize anesthetics more slowly; maximum doses should be reduced by 25-30%.
Summary
Dental local anesthetics fall into amide and ester classes with distinct pharmacokinetic profiles. Lidocaine remains the standard agent for routine procedures, while articaine's superior bone penetration makes it optimal for mandibular anesthesia. Bupivacaine provides extended post-operative anesthesia, and prilocaine offers rapid metabolism despite methemoglobinemia risks. Epinephrine extends anesthetic duration 2-3 fold by reducing vascular absorption, with maximum doses varying based on cardiac history. Understanding each agent's onset time, duration, metabolism, toxicity thresholds, and drug interactions enables rational clinical selection matched to specific procedures and patient medical conditions.